Data Sharing Statement

Kalincik. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplantation vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. *JAMA Neurol.* Published May 15, 2023. doi:10.1001/jamaneurol.2023.1184

Data

Data available: No

Additional Information

Explanation for why data not available: Data from the participating cohorts can be requested from the principal investigators, conditional after obtaining approvals from the appropriate institutional review boards. The MSBase registry is a data processor and warehouses data from individual principal investigators who agree to share their datasets on a project-by-project basis. Data access to external parties can be granted on reasonable request at the sole discretion of the principal investigators, who will need to be approached individually for permission.